A groundbreaking study presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium has shed light on significant gaps in the clinical management of metastatic castration-resistant prostate cancer (mCRPC) patients. The research revealed that 81% of patients did not undergo homologous recombination repair gene mutation (HRRm) testing at the time of diagnosis, and a concerning 35% of those who tested positive received PARP inhibitor treatment only after the third line of therapy.
Confirming Clinical Practice Gaps
The extended real-world analysis underscores a critical need for improved clinical practice in the assessment and treatment of mCRPC. Researchers noted a deficiency in both the lack of biomarker testing and delayed initiation of PARP inhibitors, indicating areas for improvement in healthcare protocols. As highlighted by the study, continuing education and standardized testing practices are essential to address these shortcomings.
Germline vs. Somatic Testing
Of the 1022 patients examined in the study, 650 (63.6%) underwent HRRm testing—either germline (21.2%), somatic (58.8%), or both (3.4%). The majority of patients had unknown testing status (16.6%). Timing played a crucial role, with only 19% receiving testing at diagnosis, 41% during or after the first line of treatment, 22% during or after the second line, and 18% at three or more lines of treatment. A small percentage experienced testing failures, particularly with somatic tissue testing.
HRRm Positivity and Treatment Implications
Testing revealed that 38% of patients were HRRm positive, with 58.4% of these treated with a PARP inhibitor. Notably, many patients received PARP inhibitors later in their treatment regimen. Among the genes identified in patients treated with PARP inhibitors were ATM (30.9%), BRCA2 (33.6%), BRCA1 and CDK12 (6.6%), CHEK2 (13.2%), RAD54L (2%), PALB2 (5.3%), and CHEK1, BRIP1, and RAD51B (0.7%). In untreated patients, 15.9% were BRCA2 positive, 29% were ATM positive, and 3.7% were BRCA1 positive, highlighting opportunities for targeted therapy.
One significant finding was that not all BRCA1/2 and ATM-positive patients received PARP inhibitor therapy, which could mean missed chances for effective treatment.
Study Methodology and Significance
The study utilized data from the IntegraConnect – Precision Q database, encompassing electronic health records from 500 US healthcare facilities. Researchers identified patients with mCRPC diagnosed or treated between January 1, 2020, and December 31, 2023. Medical curators reviewed patient charts to extract relevant data, including testing success rates, timing of germline and somatic testing, and lines of treatment involving novel hormonal therapies or PARP inhibitors.
The approval of novel hormonal therapies in combination with PARP inhibitors for first-line treatment of mCRPC motivated the researchers to expand their analysis. By examining the timing of HRRm testing and treatment initiation, researchers aimed to identify opportunities for improving patient outcomes and optimizing clinical practices.
Implications for Future Care
The findings from this study emphasize the importance of incorporating biomarker testing into standard clinical practice at the time of diagnosis. Delayed testing and suboptimal treatment alignment could lead to missed opportunities for patients. By focusing on education and standardization, healthcare providers can improve patient management and potentially enhance survival outcomes for mCRPC patients.
Call to Action
Join the conversation on how these findings can reshape the landscape of mCRPC treatment. We invite you to share your thoughts and insights below. Subscribe to our newsletter for the latest in cancer research and treatment advancements, and help us drive progress towards better patient care.